Endeavor stent set to become third DES in US after FDA panel recommendation
This article was originally published in Clinica
Executive Summary
An FDA advisory panel has unanimously recommended the zotarolimus-eluting Endeavor stent for approval as a treatment for coronary artery disease. Consequently, the Endeavor device, developed by Medtronic, is now positioned to become the third DES to enter the US market.